| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/07/2005 | US20050148523 Such as saquinavir, ritonavir, indinavir, nelfinavir, fosamprenavir, amprenavir, and lopinavir |
| 07/07/2005 | US20050148521 Coadministration with non-steroidal antiinflammatory agent allows for lower dosage of cyclophosphamide; side effect reduction; kits |
| 07/07/2005 | US20050148520 Avermectin derivatives |
| 07/07/2005 | US20050148519 Comprises non-steroidal anti-inflammatory (such as flunixin, carprofen, ibuprofen, diclofenac, and naproxen) and antibiotic (such as azithromycin, roxythromycin, tilmicosin, oxytetracycline and doxycycline) |
| 07/07/2005 | US20050148517 Carotenoid ether analogs or derivatives for controlling connexin 43 expression |
| 07/07/2005 | US20050148512 Medical implants and fibrosis-inducing agents |
| 07/07/2005 | US20050148509 Insulin-like growth factor; fusion proteins; chimera; apoptosis |
| 07/07/2005 | US20050148501 Methods of inducing ovulation using a non-polypeptide camp level modulator |
| 07/07/2005 | US20050148495 Using XMP.629 ( a peptide containing NH2-lys-leu-phe-arg-(1-naphthyl)-ala)-gln-ala-lys(3-naphthyl)-ala)CONH2 or a pharmaceutically acceptable salt or derivative as antiacne agent |
| 07/07/2005 | US20050148070 Propagating human progenitor cell using nutrient broth free of mammalian fetal serum; tissue engineering; regenerative medicine |
| 07/07/2005 | US20050148062 Transgenic microorganisms comprising apoptosis associated genes for use as tools in identifying modulators for prevention and treatment of cell proliferative disorders |
| 07/07/2005 | US20050148052 Reusing hydrochloric, sulfuric or phosphoric acid in hydrolysis of fungal biomass and generation of glucosamine and citric acid; bioreactors |
| 07/07/2005 | US20050148034 Using reduced microvessel outgrowth of pluripotent stem cells as diagnostic indicator angoigenseis inhibition; antitumor agents |
| 07/07/2005 | US20050148020 ATM kinase compositions and methods |
| 07/07/2005 | US20050148017 Antisense oligonucleotides against tenascin for the treating of vitiligo |
| 07/07/2005 | US20050148014 Regulation of human P2Y1-like G protein-coupled receptor |
| 07/07/2005 | US20050148012 BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells |
| 07/07/2005 | US20050147729 Combination of sitostanol and campestanol components; food additives; inhibiting intestinal cholesterol absorption |
| 07/07/2005 | US20050147701 Anti-prostate cancer composition and therapeutic uses therefor |
| 07/07/2005 | US20050147698 dietary supplements for ocular nutrition; comprise DHA (docosahexaenoic acid) |
| 07/07/2005 | US20050147695 Method of preventing parturient hypocalcemia in animals and compositions used therein |
| 07/07/2005 | US20050147689 Method for inhibiting the growth of gastrointestinal tract tumors |
| 07/07/2005 | US20050147681 Multi-arm block copolymers as drug delivery vehicles |
| 07/07/2005 | US20050147680 Injectable veterinary composition for small animals |
| 07/07/2005 | US20050147678 Controlled release oral dosage form |
| 07/07/2005 | US20050147675 Composition for the treatment and prevention of endothelial dysfunction |
| 07/07/2005 | US20050147674 A tablet or capsule prepared from a mixture of crystalline escitalopram oxalate having a median particle size of > 40 mu m and excipients; large particle size for use in direct compression; controlled crystallization from solution to avoid granulation and drying steps; binder-and lactose-free |
| 07/07/2005 | US20050147672 Tablets quickly disintegrating in mouth |
| 07/07/2005 | US20050147671 A fast-release dosage of diclofenac or diclofenzc salts in the form of a packet of powder for dissolving or suspending in water or a high-speed release layer in a bilayered tablet that comprises a fast and a slow layer; palatable and free from aftertaste and side effects; consistancy; uniformity |
| 07/07/2005 | US20050147670 Oral disintegrating dosage forms |
| 07/07/2005 | US20050147669 Rapid dissolution formulation of a calcium receptor-active compound |
| 07/07/2005 | US20050147666 Rapidly disintegrates in the oral cavity without water and has a practical hardness; comprises a water soluble active ingredient, D-mannitol in the form of crystals or fine particles and crospovidone |
| 07/07/2005 | US20050147665 Consisting of eicosapentaenoic acid or derivative, vitamin B 12, folic acid, at a maximum daily dose of 5 mg, and vitamin B6, at a maximum daily dose of 20 mg, and optionally at least one antioxidant; treatment of psychiatric disorders; schizophrenia, Alzheimer's disease, dementia, Parkinson's disease |
| 07/07/2005 | US20050147663 Drug dosage form containing active material and disintegrant in core covered with protective , swellable and enteric coatings |
| 07/07/2005 | US20050147662 Compounds and compositions for delivering active agents |
| 07/07/2005 | US20050147660 Peptide-carrying bodies for immune response |
| 07/07/2005 | US20050147659 Oil/water/oil double microemulsion incorporated into solid support constituted by microporous inorganic substance or by an adsorbent colloidal inorganic substance or cross-linked swellable in water polymer, wherein drug is dissolved or dispersed in one or more phases of microemulsion; improved solubility |
| 07/07/2005 | US20050147649 Method and dietary composition for improving fat digestibility |
| 07/07/2005 | US20050147648 Comprising two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate production of glutathione; macular degeneration |
| 07/07/2005 | US20050147643 Treating varicose or veins by injecting a composition silk made of polyalkylene oxide-polyester block copolymer into the lumen of a vein; anchoring implantable medical devices into or onto biological tissue |
| 07/07/2005 | US20050147633 Insecticidal amides with nitrogen-containing benzo-Fused bicyclic ring systems |
| 07/07/2005 | US20050147631 comprising mixtures of an ornithine decarboxylase inhibitor, angiogenesis inhibitors, antiinflammatory agents and cosmetically acceptable vehicles |
| 07/07/2005 | US20050147629 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| 07/07/2005 | US20050147620 a mixture of spices creatine, statins, niacin, lipoic acid and/or red yeast rice, used as anticholesterol and antidiabetic agents |
| 07/07/2005 | US20050147607 administering interleukin antagonists, for prophylaxis of respiratory system disorders |
| 07/07/2005 | US20050147604 Means and methods for diagnosing and treating affective disorders |
| 07/07/2005 | US20050147599 Medical implants and fibrosis-inducing agents |
| 07/07/2005 | US20050147598 Combining with animal fat, vegetable oil and/or polyol; oxidation resistance; shelf life |
| 07/07/2005 | US20050147591 Methods and compositions for viral enhancement of cell killing |
| 07/07/2005 | US20050147585 Gelling inverse thermosensitive polymer in vasculature site for temporary occlusion while maintaining vessels cylindrical shape |
| 07/07/2005 | US20050147584 Compositions and methods comprising memantine and polyanionic polymers |
| 07/07/2005 | US20050147583 Carbamylation to form a water soluble prodrug that has a biologically active agent linked to a water soluble non-immunogenic polymer; a hydrolyzing through carbamate bond; drug delivery; no enzymes or catalysts needed for release of acitve agent |
| 07/07/2005 | US20050147582 Polypropylene bottle with nitrile copolymer inner liner; shelf life; octyl cyanoacrylate; surgical tissue bonding |
| 07/07/2005 | US20050147581 Molar ratio of acidic polymer to protein therapeutic in excess of stoichiometric requirement; such as pulmonary delivery of somatropin |
| 07/07/2005 | US20050147580 Therapy for kidney diseasel removal phosphates; gastrointestinal disorders |
| 07/07/2005 | US20050147577 Composition for pharmaceutical or dietetic use for combating hair loss |
| 07/07/2005 | US20050147574 Inhibitors of proteasomal activity for stimulating hair growth |
| 07/07/2005 | US20050147570 Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne |
| 07/07/2005 | US20050147569 Aqueous slurries useful for cleaning the tongue and throat and methods related thereto |
| 07/07/2005 | US20050147567 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 07/07/2005 | US20050147565 using inhalants containing aerosol suspensions comprising mometasone furoate, formoterol fumarate and 1,1,1,2,3,3,3,-heptafluoropropane |
| 07/07/2005 | US20050147564 Inhalable formulation of a solution containing a tiotropium salt |
| 07/07/2005 | US20050147562 for treating or preventing gastroesophageal reflux disease (GERD) |
| 07/07/2005 | DE10392718T5 Pharmazeutische Formulierung in einem Medikamentenfreisetzungssystem und Verfahren zur Herstellung derselben A pharmaceutical formulation in a drug release system and method for manufacturing the same |
| 07/07/2005 | DE10392417T5 Verwendung von Tagatose in Laxanzien Use of tagatose in laxatives |
| 07/07/2005 | DE10358525A1 Endoparasitizide Mittel zur topischen Applikation Endoparasiticidal compositions for topical application |
| 07/07/2005 | DE10357970A1 Lösungsmittel für biogene pharmazeutische Wirkstoffe Solvent for biogenic active pharmaceutical ingredients |
| 07/07/2005 | DE10357510A1 Heteroarylsubstituierte Benzole Heteroaryl-substituted benzenes |
| 07/07/2005 | DE10357451A1 Wirkstoffkombinationen aus 2,3-Dibenzylbutyrolactonen und Licochalcon A oder einem wässrigen Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A Active compound combinations of 2,3-Dibenzylbutyrolactonen and licochalcone A or an aqueous extract of Radix Glycyrrhizae inflatae containing licochalcone A |
| 07/07/2005 | DE10356815A1 Use of an angiotensin II receptor antagonist for treating type 2 diabetes or prediabetes, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure |
| 07/07/2005 | DE10356567A1 Radiosensibilisatoren und Herstellungsverfahren Radiosensitizers and methods of manufacture |
| 07/07/2005 | DE10356409A1 Neues Arzneimittel Oxachelin und Derivate New drug Oxachelin and derivatives |
| 07/07/2005 | DE10356406A1 Medicaments with calcium ion channel inhibiting action, useful e.g. for treating hypertension, cardiomyopathy, ataxia, migraine or epilepsy, containing new or known collybolide compounds |
| 07/07/2005 | DE10354894A1 Orale Formulierungen des Desoxypeganins und deren Anwendungen Oral formulations of deoxypeganine and their applications |
| 07/07/2005 | DE102004057758A1 Synergistic composition containing arginine and folic acid, useful for treatment and prevention of e.g. arterial hypertension and arteriosclerosis |
| 07/07/2005 | CA2792483A1 Hiv protease inhibiting sulfonamides |
| 07/07/2005 | CA2551543A1 Method of suppressing cancer |
| 07/07/2005 | CA2551190A1 Polypeptides for modulating binding of trp channel proteins and trp-associated proteins. |
| 07/07/2005 | CA2551186A1 Element sulfur as an oral or parental medical product |
| 07/07/2005 | CA2551183A1 Process for producing pellets for pharmaceutical compositions |
| 07/07/2005 | CA2551181A1 Glycosaminoglycan (gag) mimetics |
| 07/07/2005 | CA2550847A1 Nicotinic acetylcholine receptor ligands |
| 07/07/2005 | CA2550844A1 Nicotinic acetylcholine receptor ligands |
| 07/07/2005 | CA2550843A1 Novel phenylalanine derivatives |
| 07/07/2005 | CA2550839A1 Antharquinone compounds as anti cancer compounds |
| 07/07/2005 | CA2550657A1 Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation |
| 07/07/2005 | CA2550655A1 Nicotinic acetylcholine receptor ligands |
| 07/07/2005 | CA2550643A1 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof |
| 07/07/2005 | CA2550485A1 Polymorphic form b2 of ziprasidone base |
| 07/07/2005 | CA2550447A1 Methods and materials for assessing prostate cancer therapies |
| 07/07/2005 | CA2550300A1 Polymetaphosphate based formulations for therapy of microcrystalline arthropathies |
| 07/07/2005 | CA2550298A1 Reduction of toxicity of multi-targeting antifolates |
| 07/07/2005 | CA2550283A1 Crystalline form of 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1h-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol |
| 07/07/2005 | CA2550258A1 Oligomeric compounds for the modulation of bcl-2 |
| 07/07/2005 | CA2550257A1 1-akan-2-ol substituted piperazine and piperidine compounds |
| 07/07/2005 | CA2550215A1 Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| 07/07/2005 | CA2550091A1 Methods of treating a disorder |
| 07/07/2005 | CA2550071A1 Pharmaceutical compositions |
| 07/07/2005 | CA2550064A1 Methods of treating acute inflammation in animals with p38 map kinase inhibitors |
| 07/07/2005 | CA2549966A1 Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle |